Philadelphia University + Thomas Jefferson University

Caro, J. Jaime

< Back

Profile

J. Jaime Caro, MDCM, FRCPC, FACP

J. Jaime Caro, MDCM, FRCPC, FACP

Contact Dr. Caro

901 Walnut Street
10th Floor
Philadelphia, PA 19107

(215) 503-0174
(215) 923-7583 fax

Education

MDCM, McGill University (Canada)

Residency

Internal Medicine, Royal Victoria Hospital (Canada)

Fellowship

Epidemiology and Biostatistics, McGill University (Canada)
Clinical Research, Royal Victoria Hospital (Canada)

University Appointments

Lecturer, Jefferson College of Population Health

Research & Practice Interests

Economic Modeling
Epidemiology
Biostatistics
Health Technology Assessment

Teaching

Simulation for Economic Evaluation

Biography

Dr. Jaime Caro is Chief Scientist at Evidera where he focuses on developing and applying novel techniques in modeling, health economics, comparative effectiveness, epidemiology and outcomes research. Dr. Caro trained at McGill University, where he practiced internal medicine and continues as Adjunct Professor of Medicine and Adjunct Professor of Epidemiology & Biostatistics. Dr. Caro also teaches at the Thomas Jefferson University College of Population Health and the Massachusetts College of Pharmacy & Health Sciences.

Dr. Caro continues to pioneer new methodologies in health economic modeling, discrete event simulation to model diseases and their treatment, Simulated Treatment Comparison to provide comparative effectiveness information in the absence of head-to-head trials, simulation techniques to make post-marketing registries more feasible and efficient and health technology assessments.

Publications

Most Recent Peer-Reviewed Publications

  1. Amplifying Each Patient’s Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients
  2. The Use of MCDA in HTA: Great Potential, but More Effort Needed
  3. Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics
  4. Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics
  5. Advantages and disadvantages of discrete-event simulation for health economic analyses
  6. Erratum: A modeling study questionnaire to assess study relevance and credibility to inform health care decision making: An ISPOR-AMCP-NPC good practice task force report (Value Health (2014) 17:2 (174-182))
  7. Brief Latin American Update: One More ViHRI Annual Issue, and Another Exciting Biennial ISPOR Conference
  8. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers
  9. What Is Insufficient about Validation?
  10. Psst, have i got a model for you...
  11. One small step for latin America, one more leap for value in health regional issues
  12. Introducing the New Value in Health Regional Issues Journal: The Latin America Region Edition
  13. The importance of patient-reported outcomes: A call for their comprehensive integration in cardiovascular clinical trials
  14. Decision-Analytic Models: Current Methodological Challenges
  15. Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature
  16. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: An ISPOR-AMCP-NPC good practice task force report
  17. Budget impact analysis - Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force
  18. ISPOR-SMDM task force's recommendations for good modeling practices - Reply to letter to the editor by Corro Ramos
  19. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: A cost-effectiveness analysis for the United States
  20. Treating acetaminophen overdose: Thresholds, costs and uncertainties